IP Library › Granted Patent US 9,453,222

Granted Patent B2

US 9,453,222 · App. 14/582,284 · Granted Sep 27, 2016

Ligand-conjugated monomers

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 9,453,222
App. No.: 14/582,284
Granted: Sep 27, 2016
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

This invention relates composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression.

Claims (72)

1. A method of inhibiting a target gene comprising providing a conjugate to a cell, wherein the conjugate comprises an oligonucleotide agent that can target a substantially complementary miRNA and a ligand, and wherein at least one subunit having a formula (I) is incorporated into said oligonucleotide agent:

wherein:

X is N(CO)R 7 , NR 7 or CH 2 ;

Y is NR 8 , O, S, CR 9 R 10 , or absent;

Z is CR 11 R 12 or absent;

Each of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is, independently, H, OR a , OR b , (CH 2 ) n OR a , or (CH 2 ) n OR b , provided that at least one of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is OR a or OR b and that at least one of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is (CH 2 ) n OR a , or (CH 2 ) n OR b ;

Each of R 5 , R 6 , R 11 , and R 12 is, independently, H, C 1 -C 6 alkyl optionally substituted with 1-3 R 13 , or C(O)NHR 7 ; or R 5 and R 11 together are C 3 -C 8 cycloalkyl optionally substituted with R 14 ;

R 7 is R d ; or C 1 -C 20 alkyl substituted with NR c R d or NHC(O)R d ;

R 8 is C 1 -C 6 alkyl;

R 13 is hydroxy, C 1 -C 4 alkoxy, or halo;

R 14 is NR c R 7 ;

R a is:

R b is:

Each of A and C is, independently, O or S;

B is OH, O − , or

R c is H or C 1 -C 6 alkyl;

R d is the ligand; and

n is 1-4.

2. The method of claim 1 , wherein said conjugate is administered to an organism.

3. The method of claim 1 , wherein said cell is outside an organism.

4. The method of claim 3 , wherein said cell is a cell of a cell line.

5. A method of modulating expression of a target gene in a subject, the method comprising administering an conjugate to a subject, wherein the conjugate comprises an oligonucleotide agent that can target a substantially complementary miRNA and a ligand, wherein at least one subunit having a formula (I) is incorporated into said oligonucleotide agent:

wherein:

X is N(CO)R 7 , NR 7 or CH 2 ;

Y is NR 8 , O, S, CR 9 R 10 , or absent;

Z is CR 11 R 12 or absent;

R 7 is R d ; or C 1 -C 20 alkyl substituted with NR c R d or NHC(O)R d ;

R 8 is C 1 -C 6 alkyl;

R 13 is hydroxy, C 1 -C 4 alkoxy, or halo;

R 14 is NR c R 7 ;

R a is:

R b is:

Each of A and C is, independently, O or S;

B is OH, O − , or

R c is H or C 1 -C 6 alkyl;

R d is the ligand; and

n is 1-4.

6. A method of treating a kidney, ocular, or viral disorder, said method comprising administering a conjugate to a subject, wherein the conjugate comprises an oligonucleotide agent that can target a substantially complementary miRNA and a ligand, wherein at least one subunit having a formula (I) is incorporated into said oligonucleotide agent:

wherein:

X is N(CO)R 7 , NR 7 or CH 2 ;

Y is NR 8 , O, S, CR 9 R 10 , or absent;

Z is CR 11 R 12 or absent;

R 7 is R d ; or C 1 -C 20 alkyl substituted with NR c R d or NHC(O)R d ;

R 8 is C 1 -C 6 alkyl;

R 13 is hydroxy, C 1 -C 4 alkoxy, or halo;

R 14 is NR c R 7 ;

R a is:

R b is:

Each of A and C is, independently, O or S;

B is OH, O − , or

R c is H or C 1 -C 6 alkyl;

R d is the ligand; and

n is 1-4.

7. The method of claim 1 , wherein X is N(CO)R 7 or NR 7 , Y is CR 9 R 10 , and Z is absent.

8. The method of claim 7 , wherein R 7 is (CH 2 ) 5 NHR d or (CH 2 ) 5 NHC(O)R d .

9. The method of claim 1 , wherein the R d ligand is a steroid radical optionally tethered to at least one carbohydrate radical; a folic acid radical; a carbohydrate radical; a vitamin A radical; a vitamin E radical; a vitamin K radical; or a vitamin B 12 radical.

10. The method of claim 9 , wherein the R d ligand is a carbohydrate cholesterol radical.

11. The method of claim 1 , wherein the miRNA is selected from the group consisting of miR-21, miR-16, miR-22, miR-122, miR-155, miR-192, miR-194, and miR-375.

12. The method of claim 5 , wherein X is N(CO)R 7 or NR 7 , Y is CR 9 R 10 , and Z is absent.

13. The method of claim 12 , wherein R 7 is (CH 2 ) 5 NHR d or (CH 2 ) 5 NHC(O)R d .

14. The method of claim 5 , wherein the R d ligand is a steroid radical optionally tethered to at least one carbohydrate radical; a folic acid radical; a carbohydrate radical; a vitamin A radical; a vitamin E radical; a vitamin K radical; or a vitamin B 12 radical.

15. The method of claim 14 , wherein the R d ligand is a carbohydrate cholesterol radical.

16. The method of claim 5 , wherein the miRNA is selected from the group consisting of miR-21, miR-16, miR-22, miR-122, miR-155, miR-192, miR-194, and miR-375.

17. The method of claim 6 , wherein X is N(CO)R 7 or NR 7 , Y is CR 9 R 10 , and Z is absent.

18. The method of claim 17 , wherein R 7 is (CH 2 ) 5 NHR d or (CH 2 ) 5 NHC(O)R d .

19. The method of claim 6 , wherein the R d ligand is a steroid radical optionally tethered to at least one carbohydrate radical; a folic acid radical; a carbohydrate radical; a vitamin A radical; a vitamin E radical; a vitamin K radical; or a vitamin B 12 radical.

20. The method of claim 19 , wherein the R d ligand is a carbohydrate cholesterol radical.

21. The method of claim 6 , wherein the miRNA is selected from the group consisting of miR-21, miR-16, miR-22, miR-122, miR-155, miR-192, miR-194, and miR-375.

Assignments (1)

SECURITY INTEREST Recorded Oct 1, 2025

From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.

To: BANK OF AMERICA, N.A.

Reel/Frame 072996/0337 →